Quality of Evidence:
Coadministration has not been studied. Lopinavir/ritonavir is metabolised by CYP3A and inhibits CYP3A. Chloroquine is metabolised by CYPs 2C8, 3A4 and 2D6, and is also eliminated unchanged via the kidney (50%). No effect on lopinavir/ritonavir is expected, but inhibition of CYP3A by lopinavir/ritonavir may increase chloroquine concentrations (although to a moderate extent due to the multiple elimination pathways), thereby increasing the risk of QT prolongation as both drugs have risks of QT prolongation and/or TdP on the CredibleMeds.org website (known risk for chloroquine; possible risk for lopinavir). Due to the very long half-life, the risk of QT prolongation may persist even after discontinuation of chloroquine. No dosage adjustment is recommended for chloroquine but ECG monitoring is advised.
View all available interactions with
Lopinavir/ritonavir (LPV/r) by clicking